Richard L. Schilsky
MD, FACP, FSCT, FASCO
Chairman, WIN Consortium, Professor Emeritus, University of Chicago Past President and Former Executive Vice President and Chief Medical Officer (ASCO), USA
Vice Chairman, WIN Consortium, Head, Medical Oncology Department, Vall d’Hebron Institute of Oncology, President 2018 - 2019, European Society for Medical Oncology (ESMO)
MD, CM, CQ, FRCP(C), FACP, FCAHS
Professor of Medicine and Oncology at McGill University, Director of the Segal Cancer Centre, Canada
Chief Scientific and Operating Officer, WIN Consortium, France
Head of Standard Operating Procedures and Repository Committee, WIN Consortium Chair, Institute of Pulmonology Oncology, Sheba Medical Center, Israel
Chief Medical Officer, WIN Consortium
March 14, 2021
|08:30||Welcome and Opening Remarks - What The Future Holds in Precision Oncology|
|09:20||Session 1 - Beyond DNA Testing: The Place of Transcriptomics in Precision Oncology|
|14:30||Session 2 -Innovation in Clinical Trials to Enable Future Efficient Treatments|
|16:45||Poster viewing, networking|
|18:00||Satellite symposium (to be confirmed)|
|19:00||Poster viewing, welcome reception|
March 15, 2021
|08:30||Session 3 - Disruptive Concepts and Methodological Innovations in NSCLC: Meet the Experts|
|11:30||Session 4 - WIN First International Molecular Tumor Board: A Strategic Place in Advancing Precision Oncology|
|14:00||Session 5 - What is New in Breast, CRC, Ovary, Head & Neck, Prostate, Kidney, Pediatric Cancers?|
|16:55||Best Two Posters Presentations and Awards|
The audience of the Symposium spans a wide range of high-profile stakeholders in clinical and non-clinical cancer research, technology development and patient management. WIN Symposia attracts an international audience with 50% coming from Europe, 25% from Americas, 15% Middle East & Africa and 10% Asia & Oceania.
Attendees who are for the vast majority (80%) physicians (or physicians in training), need to understand the role of the current biomarkers, their optimal application, and the emerging new omic tests that will inform future biomarker adoption.
Treating patients without understanding the established and emerging molecular markers for cancer can affect virtually every patient with cancer and every aspect of cancer care, since there are multiple FDA and EMA approved omic biomarkers to refine prognosis, select therapy and/or clinical trials and monitor for cancer recurrence.
There are now biomarkers for selection of hormonal therapies, targeted therapies and immunotherapy. We would like attendees to understand the role of these biomarkers, their optimal application, and the emerging new omic tests that will inform future biomarker adoption.
We will discuss in particular the inclusion of transcriptomics in the biomarker armamentarium, that will require novel algorithms and improved quality of biopsies.
The symposium will also present its first international Molecular Tumor Board to exemplify with patients' concrete cases, submitted by meeting attendees, how to use biomarkers to inform therapeutic choice.
The overall learning objectives are:
The CME request for the WIN 2022 Symposium is pending, for 13 hours of European external CME credits by the European Accreditation Council for Continuing Medical Education (EACCME®).
The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.eu
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/education/cme/claim-cme-credit-ama
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
Endorsement applications are currently under preparation.
Information on registration and abstract submission will be released on this website, make sure you have registered your interest to receive updates
WIN Symposium series endorsed by:
ASCO® is a registered trademark of the American Society of Clinical Oncology®.
Used with permission. This is not an ASCO sponsored event.
WIN series recommended by:
Listen to 30 Precision Oncology leaders from academia, industry and research organizations.
View over 70 thought provoking abstracts from like-minded professionals.
Showcase your work.
Engage in the open discussions and network with other professionals in oncology.
WIN 2022 Symposium
c/o MCI UK Ltd